Moderna (MRNA) – Upgrades
-
Oppenheimer lifts Moderna (MRNA) rating on key 2024/2025 catalysts
-
Oppenheimer Upgrades Moderna (MRNA) to Outperform on visibility on COVID-19 vaccine sales, OPEX progression and 2024/25 catalysts
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Back to MRNA Stock Lookup